Not for emergencies. Call 911 if experiencing medical emergency.
Tesamorelin (brand name Egrifta SV) is a stabilized GHRH analog with a clearer regulatory record than most peptides discussed in wellness contexts. The active ingredient is FDA-approved for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, and that narrower approved setting matters when broader body-composition claims are being considered.
Tesamorelin's structural modification extends activity compared with native GHRH and is part of why clinicians compare it with sermorelin rather than treating the two as interchangeable. The most defensible discussion stays anchored to the approved HIV-associated lipodystrophy context, then distinguishes clearly between that evidence base and broader off-label interest.
Pivotal randomized trials in HIV-associated lipodystrophy showed reduction in visceral adipose tissue using direct imaging endpoints. This is the clearest evidence anchor for tesamorelin and the basis of FDA approval.
Published clinical literature consistently frames IGF-1 and metabolic monitoring as part of the tesamorelin conversation, reinforcing why clinician review matters more than simple potency language.
Investigational data suggest liver-fat and fibrosis-progression effects in a specific HIV-associated population. That may be useful context, but it should not be treated as a blanket approval for broader metabolic use.
Official labeling remains the cleanest source for the approved indication, core safety framing, and why broader body-composition interest should be discussed as a narrower evidence question rather than an assumption.
High
Tesamorelin's evidence is strongest in its specific FDA-approved population and is backed by randomized trial data with direct visceral-fat measurement. Evidence becomes less certain when patients or marketers stretch that narrower record into broader body-composition claims.
FDA approval is specific to HIV-associated lipodystrophy. Broader use involves off-label extrapolation. Monitoring questions can include IGF-1, glucose, injection tolerance, and whether the intended goal actually matches the evidence base.
Risk, contraindications, and monitoring, including IGF-1 and metabolic context, should be reviewed with a licensed clinician before initiating tesamorelin. This content is educational and does not replace individualized medical advice.
This page is educational content from the New Blue Health Clinical Content Team. It is reviewed under the New Blue Health Medical Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.